ANDA 212133, held by Ascent Pharmaceuticals. Hydromorphone Hydrochloride.
As of Nov 18, 2026, ANDA 212133 (Hydromorphone Hydrochloride), held by Ascent Pharmaceuticals, was first approved by FDA on Sep 23, 2020, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 23, 2020 | Original application | Approved |
| Hydromorphone Hydrochloride8MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride12MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride16MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride32MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 13REMS | Approved | None posted |
| Dec 22, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 9, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 5REMS | Approved | None posted |
| Dec 15, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 23, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters